Skip to main content

View full-text article in PMC

. 2013 Aug 21;8(8):e71985. doi: 10.1371/journal.pone.0071985

Table 3. Comparison of clinical characteristics between subjects with and without the Pro12Ala variant of PPARγ2.

Variable	All Subjects			T2DM			NGT
	Pro/Ala and Ala/Ala	Pro/Pro	P	Pro/Ala and Ala/Ala	Pro/Pro	P	Pro/Ala and Ala/Ala	Pro/Pro	P
Number	303	2843	–	85	1060	–	218	1783	–
Age (years)	45.7±11.1	46.0±11.9	0.623	51.4±10.7	50.4±11.0	0.435	43.4±10.4	43.5±11.7	0.976
BMI (kg/m²)	23.4±3.8	24.1±3.8	0.006^b	24.8±4.0	25.1±3.9	0.472	22.9±3.6	23.4±3.7	0.040^b
HOMA-IR^a	2.9±2.1	3.2±3.1	0.152	4.1±3.2	4.4±4.5	0.494	2.4±1.1	2.4±1.3	0.774
HOMA-beta^a	97.3±65.8	88.3±75.7	0.046^b	49.2±60.6	46.5±72.6	0.749	116.1±57.8	113.1±66.0	0.524
HDL-C (mmol/L)	1.5±0.6	1.4±0.7	0.573	1.6±1.0	1.5±0.9	0.192	1.4±0.4	1.4±0.6	0.837
Total cholesterol (mmol/L)	4.5±1.1	4.5±1.1	0.837	4.8±1.4	4.7±1.3	0.596	4.4±1.0	4.4±0.9	0.823
Triglyceride (mmol/L)	1.7±1.2	1.7±1.3	0.756	2.1±2.1	2.1±1.6	0.745	1.5±0.9	1.5±1.1	0.843

All data are means±SD.

The abbreviations used see Table 1 and 2.

^a

Calculated using fasting plasma glucose (mmol/L) and fasting plasma insulin (mU/L) levels.

^b

P<0.05.